7 of 10 active EoE trials reach primary completion in 2026. How to watch a readout window.

Eosinophilic esophagitis (EoE) has a readout window open right now. Of 10 active interventional Phase 1–3 trials, 7 reach primary completion in 2026. Three already report it as actual. Watching that window well means reading three registry fields together, not one: the date, whether the date is actual or estimated, and when the sponsor last verified the record.

Timeline · primary completionReal data

7 of 10 active EoE trials reach primary completion in 2026

Signal 1: an actual date means the data exists

When a sponsor switches primary completion from estimated to actual, data collection for the primary endpoint is over. The most important one here is a 368-participant Phase 3 trial (NCT05583227) with actual primary completion on 14 Jul 2026. The registry will not tell you when topline results come out; press releases, earnings calls and congress abstract deadlines will. From this point every week without news is information.

Signal 2: a passed estimate on an old record is unconfirmed, not late

NCT06705387 lists an estimated primary completion of Sep 2026, but its record was last verified in Mar 2025. NCT05485155 is close behind: estimated Oct 2026, last verified May 2025. Calling either of them delayed would be a guess. The defensible label is unconfirmed, and the right action is to ask: an investigator contact, a conference update, the sponsor's pipeline page.

Signal 3: estimates still ahead are where slippage shows first

A second Phase 3 (NCT06596252, 308 participants) carries an estimated primary completion of Dec 2026. The earliest public sign of slippage is usually a quiet edit to that estimate, long before any announcement. That makes the edit history more valuable than the date itself.

Register · the ten trialsReal data

Trial	Phase	Status	n	Primary completion	Date type	Verified
NCT05831176	Phase 2	Active, not recruiting	22	23 Feb 2026	Actual	Jun 2026
NCT05583227	Phase 3	Active, not recruiting	368	14 Jul 2026	Actual	Jul 2026
NCT06705387	Phase 2	Recruiting	72	Sep 2026	Estimated · stale	Mar 2025
NCT06851559	Phase 2	Active, not recruiting	95	11 Sep 2026	Actual	Oct 2026
NCT05485155	Phase 2	Recruiting	15	Oct 2026	Estimated · stale	May 2025
NCT05608681	Phase 1 / Phase 2	Recruiting	117	Dec 2026	Estimated	Mar 2026
NCT06596252	Phase 3	Active, not recruiting	308	Dec 2026	Estimated	Aug 2026
NCT06598462	Phase 2	Active, not recruiting	184	30 Apr 2027	Estimated	Mar 2026
NCT07112378	Phase 3	Recruiting	20	19 Jun 2028	Estimated	Sep 2026
NCT07588568	Phase 2	Recruiting	52	Feb 2030	Estimated	Sep 2026

A readout watch is a diff, not a snapshot: the same four fields for every trial, compared week on week, with every change recorded. That is exactly what the Comphas diff view and frozen datasets are built for.

Run it yourself

Every number above came from a query you can repeat. Ask the registry the same question for your own indication; the answer is drawn live, with its source and query time.

Method and queries

ClinicalTrials.gov API v2, pulled 17 Oct 2026. Query: condition "eosinophilic esophagitis"; overall status recruiting, not yet recruiting, active not recruiting or enrolling by invitation; StudyType INTERVENTIONAL; Phase 1, 2 or 3; all sponsor classes. Fields: PrimaryCompletionDate and its type (actual or estimated), StatusVerifiedDate, EnrollmentCount, Phase, OverallStatus. "Today" is 17 Oct 2026.